Trials with immunotherapy in combination with chemotherapy regimens in the adjuvant setting have been still ongoing, in particular for stage III colon cancer with MSI, extended to patients with POLE exonuclease domain mutation, confirming the peculiar role of this specific subgroup of patients and the need to further investigate their clinical characteristics and response to therapy [48,49]. This evidence concerns the gene POLE and colonic neoplasm.